SG/CALL/EDWARDS LIFESCIENCES/85/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 01:10:03 22/06/2024 am IST | ||
| 1.33 EUR | +1.53% |
|
| Current month | +14.78% | ||
| 1 month | -8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 1.32 | +0.76% |
| 20/24/20 | 1.31 | +12.93% |
| 19/24/19 | 1.16 | -5.69% |
| 18/24/18 | 1.23 | +7.89% |
| 17/24/17 | 1.14 | -2.56% |
Real-time Boerse Frankfurt Warrants
Last update June 22, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU26AD |
| ISIN | DE000SU26AD4 |
| Date issued | 05/12/2023 |
| Strike | 85 $ |
| Maturity | 20/12/2024 (180 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.12 € |
|---|---|
| Lowest since issue | 0.83 € |
| Spread | 0.01 € |
| Spread % | 0.74% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.9
USD
Average target price
96.05
USD
Spread / Average Target
+5.67%
- Stock Market
- Warrants
- Warrant
